Utilisation de l'anti-CD20 (rituximab) dans le traitement des lymphomes non Hodgkiniens au centre hospitalier de Saint-Brieuc

E. Legris; Eric Jobard; P. Morice; M. F. Godon

Utilisation de l'anti-CD20 (rituximab) dans le traitement des lymphomes non Hodgkiniens au centre hospitalier de Saint-Brieuc

E. Legris, Eric Jobard, P. Morice, M. F. Godon

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

Rituximab is a chimeric mouse/human monoclonal antibody which binds to CD20 antigen, a transmembrane protein, located on both normal B-cells and malignant B-cells. Rituximab is now marketed for use in the treatment of patients with follicular Non Hodgkin's Lymphoma (NHL) who are chemoresistant or are in their second or subsequent relapse after chemotherapy and the treatment of diffuse large-B-cell lymphoma in association with CHOP chemotherapy. After a synthetic presentation of the different clinical studies published with rituximab in NHL, we have chosen to present the use of the anti-CD20 in Saint-Brieuc Hospital.

Titre traduit de la contribution	Use of anti-CD20 (rituximab) in the treatment of non-Hodgkin's lymphoma in Saint-Brieuc Hospital
langue originale	Français
Pages (de - à)	69-77
Nombre de pages	9
journal	Journal de Pharmacie Clinique
Volume	22
Numéro de publication	2
état	Publié - 1 janv. 2003

mots-clés

Anti-CD20 antibody
Non Hodgkin's lymphoma
Rituximab

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{2cefec319d1f488bb05f2c82b9222e13,

title = "Utilisation de l'anti-CD20 (rituximab) dans le traitement des lymphomes non Hodgkiniens au centre hospitalier de Saint-Brieuc",

abstract = "Rituximab is a chimeric mouse/human monoclonal antibody which binds to CD20 antigen, a transmembrane protein, located on both normal B-cells and malignant B-cells. Rituximab is now marketed for use in the treatment of patients with follicular Non Hodgkin's Lymphoma (NHL) who are chemoresistant or are in their second or subsequent relapse after chemotherapy and the treatment of diffuse large-B-cell lymphoma in association with CHOP chemotherapy. After a synthetic presentation of the different clinical studies published with rituximab in NHL, we have chosen to present the use of the anti-CD20 in Saint-Brieuc Hospital.",

keywords = "Anti-CD20 antibody, Non Hodgkin's lymphoma, Rituximab",

author = "E. Legris and Eric Jobard and P. Morice and Godon, {M. F.}",

year = "2003",

month = jan,

day = "1",

language = "Fran{\c c}ais",

volume = "22",

pages = "69--77",

journal = "Journal de Pharmacie Clinique",

issn = "0291-1981",

number = "2",

}

TY - JOUR

T1 - Utilisation de l'anti-CD20 (rituximab) dans le traitement des lymphomes non Hodgkiniens au centre hospitalier de Saint-Brieuc

AU - Legris, E.

AU - Jobard, Eric

AU - Morice, P.

AU - Godon, M. F.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Rituximab is a chimeric mouse/human monoclonal antibody which binds to CD20 antigen, a transmembrane protein, located on both normal B-cells and malignant B-cells. Rituximab is now marketed for use in the treatment of patients with follicular Non Hodgkin's Lymphoma (NHL) who are chemoresistant or are in their second or subsequent relapse after chemotherapy and the treatment of diffuse large-B-cell lymphoma in association with CHOP chemotherapy. After a synthetic presentation of the different clinical studies published with rituximab in NHL, we have chosen to present the use of the anti-CD20 in Saint-Brieuc Hospital.

AB - Rituximab is a chimeric mouse/human monoclonal antibody which binds to CD20 antigen, a transmembrane protein, located on both normal B-cells and malignant B-cells. Rituximab is now marketed for use in the treatment of patients with follicular Non Hodgkin's Lymphoma (NHL) who are chemoresistant or are in their second or subsequent relapse after chemotherapy and the treatment of diffuse large-B-cell lymphoma in association with CHOP chemotherapy. After a synthetic presentation of the different clinical studies published with rituximab in NHL, we have chosen to present the use of the anti-CD20 in Saint-Brieuc Hospital.

KW - Anti-CD20 antibody

KW - Non Hodgkin's lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0043171017&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0043171017

SN - 0291-1981

VL - 22

SP - 69

EP - 77

JO - Journal de Pharmacie Clinique

JF - Journal de Pharmacie Clinique

IS - 2

ER -